Relay Therapeutics (NASDAQ:RLAY) CFO Sells $14,322.75 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,695 shares of the business’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $14,322.75. Following the completion of the transaction, the chief financial officer directly owned 249,301 shares in the company, valued at approximately $2,106,593.45. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40.

Relay Therapeutics Stock Up 0.8%

Relay Therapeutics stock traded up $0.06 during midday trading on Thursday, reaching $7.71. 1,788,553 shares of the stock traded hands, compared to its average volume of 2,246,533. The stock has a market cap of $1.34 billion, a P/E ratio of -4.41 and a beta of 1.55. The stock’s fifty day moving average is $7.93 and its 200-day moving average is $5.93. Relay Therapeutics, Inc. has a 12 month low of $1.77 and a 12 month high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). On average, equities analysts predict that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RLAY. Pictet Asset Management Holding SA bought a new position in shares of Relay Therapeutics during the fourth quarter valued at approximately $127,000. UBS Group AG boosted its position in Relay Therapeutics by 94.4% during the 4th quarter. UBS Group AG now owns 296,017 shares of the company’s stock valued at $2,504,000 after acquiring an additional 143,764 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in shares of Relay Therapeutics in the 4th quarter valued at $1,203,000. Vanguard Group Inc. raised its position in shares of Relay Therapeutics by 3.1% in the 4th quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock worth $81,990,000 after acquiring an additional 295,701 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Relay Therapeutics by 20.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 57,234 shares of the company’s stock worth $484,000 after purchasing an additional 9,613 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on RLAY shares. Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price on the stock in a research note on Monday. Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $6.00 to $13.00 in a research report on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Relay Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.57.

Trending Headlines about Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Neutral Sentiment: AAII published an explainer on why RLAY slid ~5.18%, summarizing market reaction and citing recent insider transactions as a driver. AAII Article
• Negative Sentiment: CFO Thomas Catinazzo sold 15,515 shares across Jan. 27–28 (13,820 shares at $7.62 and 1,695 at $8.45), totaling roughly $119k + $14k ≈ $120k in disclosed sales; ownership fell ~5.22% then 0.68%. SEC filing: Catinazzo SEC Filing
• Negative Sentiment: Insider Peter Rahmer sold 13,038 shares across Jan. 27–28 (11,684 at $7.62 and 1,354 at $8.45), about $89k + $11.4k ≈ $100k in sales; his holding decreased ~4.03% then 0.49%. SEC filing: Rahmer SEC Filing
• Negative Sentiment: Insider Donald A. Bergstrom sold 21,581 shares across Jan. 27–28 (18,895 at $7.62 and 2,686 at $8.45), about $144k + $22.7k ≈ $167k in sales; his stake fell ~4.28% then 0.64%. SEC filing: Bergstrom SEC Filing

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.